Robert Healy, MD
Neurology · Florence, SCNPI 1164400123
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 1,256 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations.
Across 1,256 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$3K
- Novartis$2K
- Biogen$1K
- Sanofi$1K
- EMD Serono, Inc.$1K
- Acadia Pharmaceuticals Inc$1K
- plus $14K from 54 others
What the payments were for
- Speaking & faculty fees$1741%
- Food & beverage$23,59699%
- Education$500%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$118
How this compares
$23,820 in reported general payments places this provider in the 85th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FinteplaFenfluramine Hcl | 13 | $192,150 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 16 | $147,216 |
| NuplazidPimavanserin Tartrate | 27 | $132,508 |
| VumerityDiroximel Fumarate | 13 | $112,595 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 11 | $105,471 |
| AubagioTeriflunomide | 11 | $101,716 |
| AmpyraDalfampridine | 15 | $65,972 |
| FycompaPerampanel | 55 | $59,407 |
| XcopriCenobamate | 40 | $45,265 |
| Oxtellar XrOxcarbazepine | 38 | $40,447 |
| VimpatLacosamide | 39 | $39,026 |
| BriviactBrivaracetam | 24 | $36,577 |
| Teriflunomide | 47 | $21,454 |
| Nurtec OdtRimegepant Sulfate | 13 | $17,969 |
| Lacosamide | 204 | $17,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla, Vimpat, Briviact | $3,164 | $267,75376 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,036 | $132,50827 claims |
| BiogenVumerity | $1,451 | $112,59513 claims |
| SanofiAubagio | $1,348 | $101,71611 claims |
| Acorda Therapeutics, IncAmpyra | $174 | $65,97215 claims |
| Eisai Inc.Fycompa | $678 | $59,40755 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr, Trokendi Xr | $643 | $48,39849 claims |
| SK Life Science, Inc.Xcopri | $919 | $45,26540 claims |
| PfizerNurtec Odt, Eliquis | $563 | $31,49628 claims |
| Neurelis, Inc.Valtoco | $174 | $14,42821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 270 neurology providers in South Carolina.
Other neurology in Florence
- Christopher ZustFlorence$39K
- Walter EvansFlorence$21K
- John BakerSumter$779K
- Robert CarlileSummerville$428K
- Mary HughesGreenville$404K
- Jose CardenasAiken$216K
- Fredy RevillaGreenville$208K
- Robert AdamsCharleston$204K
- Thomas HughesMt. Pleasant$102K
- Kathleen WoschkolupGreenville$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.